ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

2026.02.03
The Phase III BURAN trial, presented at the recent ESMO Congress, evaluated the PI3K inhibitor buparlisib plus paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who had progressed after PD-1/PD-L1 inhibitor therapy. The study failed to demonstrate improvements in progression-free survival (PFS) or overall survival (OS) compared with paclitaxel alone (median PFS: 4.1 months in both arms; median OS: 9.6 vs 9.7 months), despite a higher objective response rate (ORR) with the combination (30.3% vs 20.7%).
ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

2026.02.03
With the rapid evolution of immunotherapy–targeted therapy combinations, the management of advanced hepatocellular carcinoma (HCC) has entered a new era. Yet for patients with traditionally high-risk features—such as macrovascular invasion or extrahepatic spread—clinical outcomes have historically remained poor, posing a persistent therapeutic challenge.
[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

2026.02.03
For patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at high postoperative risk, the standard of adjuvant concurrent chemoradiotherapy (CRT) has remained unchanged since 2004—despite persistent rates of recurrence and metastasis. Recently, the NIVOPOST-OP trial, led by Yungang Tao of Gustave Roussy Cancer Center, was published in The Lancet, delivering the first definitive breakthrough in nearly 20 years.
Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

2026.02.03
On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.
Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology

2026.02.03
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together leading experts and young scholars in the field of urologic oncology, aiming to establish a high-level academic exchange platform and to jointly explore frontier topics and unresolved challenges in the diagnosis and treatment of urologic malignancies.
From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

2026.02.03
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together the emerging backbone of China’s urologic oncology community, aiming to promote standardized and innovative development in the diagnosis and treatment of urologic malignancies through cutting-edge academic discussion and clinical experience sharing.
CASH 2026 | Professor Zhijian Xiao: Precision Risk Stratification and Emerging Therapeutic Advances in MDS

CASH 2026 | Professor Zhijian Xiao: Precision Risk Stratification and Emerging Therapeutic Advances in MDS

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health priorities. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Zhijian Xiao from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into recent advances in precision risk stratification for myelodysplastic syndromes (MDS) and emerging targeted and immunotherapeutic strategies, highlighting the growing clinical importance of molecular classification in treatment decision-making.
CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into breakthroughs in FLT3 and IDH1/2 targeted therapy, precision strategies for elderly and high-risk AML populations, and MRD-guided dynamic treatment approaches, offering valuable perspectives for clinical practice and translational research.
CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA), with a focus on long-term outcomes of haploidentical transplantation, as well as optimization of transplant timing, patient stratification, and donor selection.
CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation

CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation

2026.02.01
As an emerging modality of hematopoietic stem cell transplantation, umbilical cord blood transplantation (UCBT) has demonstrated unique clinical value in the treatment of various hematologic diseases. From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading hematology experts from China and abroad to explore cutting-edge research and national health priorities. During the conference, Professor Zimin Sun from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared in-depth insights into the current clinical status, technical advantages, and evolving research landscape of UCBT.